Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287894 | 1.00 | LMNA (0.44) | LMNAL3MBTL1USP2SLCO1B1TDP1 | |
| SCHEMBL23151858 | 0.96 | USP2 (0.39) | LMNAL3MBTL1USP2SLCO1B1TDP1 | |
| SCHEMBL23151848 | 0.88 | ALDH1A1 (0.34) | LMNAL3MBTL1USP2SLCO1B1PDE4A | |
| SCHEMBL8089557 | 0.83 | LMNA (0.48) | LMNAL3MBTL1USP2SLCO1B1TDP1 | |
| SCHEMBL8082885 | 0.83 | LMNA (0.48) | LMNAL3MBTL1USP2SLCO1B1TDP1 | |
| SCHEMBL4653626 | 0.82 | LMNA (0.39) | LMNAL3MBTL1USP2SLCO1B1TDP1 | |
| SCHEMBL30530889 | 0.81 | MAPT (0.33) | — | |
| SCHEMBL1856420 | 0.81 | LMNA (0.41) | LMNAL3MBTL1USP2SLCO1B1TDP1 | |
| SCHEMBL9400689 | 0.80 | LMNA (0.36) | LMNAL3MBTL1USP2SLCO1B1TDP1 | |
| SCHEMBL4604786 | 0.80 | LMNA (0.44) | LMNAL3MBTL1USP2SLCO1B1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934582-A1 | ANTI HER2 ANTIBODY FORMULATION | Glenmark Pharmaceuticals S.A. (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-9017726-B2 | Biodegradable and thermosensitive poly(organophosphazene)-superparamagnetic nanoparticle complex, preparation method and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-28 | — | — | US | disclosed |
| WO-2014096051-A1 | ANTI HER2 ANTIBODY FORMULATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2014-06-26 | — | — | WO | disclosed |
| US-20120121517-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF | Korean Institute of Science and Technology of Seoul, Republic of Korea | 2012-05-17 | — | — | US | disclosed |
| US-4595712-A | Polyaddition product of organic polyisocyanate with condensation product of alkylene oxide with an amine in the presence of a polyol | SOCIETE CHIMIQUE DES CHARBONNAGES, S.A. (FR) | 1986-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121517-A1 | BIODEGRADABLE AND THERMOSENSITIVE POLY(ORGANOPHOSPHAZENE)-SUPERPARAMAGNETIC NANOPARTICLE COMPLEX, PREPARATION METHOD AND USE THEREOF | PHOSPHO1, HSPA2, FEM1B | LMNA 4134/4885L3MBTL1 900/4885USP2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.